Monday, October 18, 2021
News for Retirees


Medicare copays for brand new Alzheimer’s drug might attain $11,500 |

Share this…FacebookPinterestTwitterLinkedin On this undated picture from video offered by Biogen in Might 2021, vials of the treatment aducanumab are…

By Staff , in Medicare , at June 11, 2021



On this undated picture from video offered by Biogen in Might 2021, vials of the treatment aducanumab are dealt with by machines throughout manufacturing in Switzerland. On Monday, June 7, 2021, the Meals and Drug Administration authorised aducanumab, the primary new drug for Alzheimer’s illness in almost 20 years, disregarding warnings from unbiased advisers that the much-debated therapy hasn’t been proven to assist gradual the brain-destroying illness. (Biogen through AP)



Source link

Skip to content